Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 31, Number 4—April 2025
Research

Carbapenem-Resistant, Virulence Plasmid–Harboring Klebsiella pneumoniae, United States

Jianping Jiang, Tengfei Long, Adeline R. Porter, Arianne Lovey, Annie Lee, Jesse Thomas Jacob, Cesar A. Arias, Robert Bonomo, Robert Kalayjian, Yanan Zhao, Frank R. DeLeo, David van Duin, Barry N. KreiswirthComments to Author , and Liang ChenComments to Author 
Author affiliation: Hackensack-Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA (J. Jiang, T. Long, A. Lovey, A. Lee, Y. Zhao, B.N. Kreiswirth, L. Chen); National Institute of Allergy and Infectious Diseases Rocky Mountain Laboratories, Hamilton, Montana, USA (A.R. Porter, F.R. DeLeo); Emory University, Atlanta, Georgia, USA (J.T. Jacob); Houston Methodist Hospital and Houston Methodist Research Institute, Houston, Texas, USA (C.A. Arias); Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA (R.A. Bonomo); Case Western Reserve University School of Medicine, Cleveland (R.A. Bonomo); MetroHealth Medical Center, Cleveland (R. Kalayjian); University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA (D. van Duin)

Main Article

Table 2

Genomic features of isolates in study of carbapenem-resistant, virulence plasmid–harboring Klebsiella pneumoniae isolates, United States*

Genomic feature Isolate
ARLG-4622 ARLG-3254 ARLG-4744 ARLG-7683 ARLG-3484 ARLG-4720
Genome size, Mb 5.6 5.8 5.9 5.9 5.8 5.8
Plasmid number 3 3 5 5 5 5
MLST ST23 ST23 ST11 ST11 ST893 ST893
K locus type KL1 KL1 KL64 KL64 KL20 KL20
O locus type
 O1/O2v2
 O1/O2v2
 O1/O2v1
 O1/O2v1
 O3/O3a
 O3/O3a
ESBL or carbapenemase plasmids
  ESBL or carbapenemase KPC-2 KPC-2 CTX-M-65 CTX-M-65 CTX-M-15, OXA-48 CTX-M-15, OXA-48
Size, bp 107766 142552 106012 124552 185494 185434
Replicon
 repA_pKPC-2
 IncFIB(pQil)/
IncFII
 IncFII(pHN7A8)/
IncR
 IncFII/pHN7A8/
IncR
 IncL/M/IncFII/IncFIA(HI1)
 IncL/M/IncFII/IncFIA(HI1)
OmpK35/OmpK36
 WT/WT
 WT/WT
 OmpK35(IS)/
OmpK36GD
 OmpK35(IS)/
OmpK36GD
 OmpK35(IS)/OmpK36(IS)
 OmpK35(IS)/OmpK36(IS)
Other acquired AMR genes
 blaTEM-1D
 aac (3)-IIa; ant(2”)-Ia; catB3; sul1; dfrA14; blaTEM-1D
 aadA2; rmtB; fosA3; qnrS1; sul2; tet(A); dfrA14; blaTEM-1D; blaLAP-2
 aadA2; rmtB; fosA3; qnrS1; sul2; tet(A); dfrA14; 
blaTEM-1D; 
blaLAP-2
 aac(6')-Ib-cr; strA; strB; qnrB1; catB4; sul2; tet(A); dfrA14; 
blaTEM-1D; blaOXA-1
 aac(6')-Ib-cr; strA; strB; qnrB1; catB4; sul2; tet(A); dfrA14; blaTEM-1D; blaOXA-1
Other AMR-related mutations
 GyrA-87G
 None
 GyrA-83I, 87G; ParC-80I
 GyrA-83I,87G; ParC-80I
 MgrB-62% (frameshift); GyrA-83F
 MgrB-62% (frameshift); GyrA-83F
Hypervirulent plasmid size, Kb (BLASTn identity, coverage to pK2044)
 229.8 
(99%, 97%)
 223.7
(99%, 98%)
 217.8 
(99%, 92%)
 218.6 
(99%, 92%)
 164.4
(99%, 67%)
 185.4 
(99%, 67%)
Virulence genes
 iuc, iro, rmpADC(ΔrmpAC), ΔrmpA2, Δpeg-344, ybt, clb
 iuc, iro, rmpADC, ΔrmpA2, peg-344, ybt, clb
 iuc, Δiro, rmpADC, ΔrmpA2, peg-344, ybt
 iuc, Δiro, rmpADC(ΔrmpA), ΔrmpA2, peg-344, ybt
 iuc, ΔrmpA2, ybt
 iuc, ΔrmpA2, ybt
CPS mutation Δugd ΔcpsACP None None None None

*AMR, antimicrobial resistance; BLAST, https://blast.ncbi.nlm.nih.gov; CPS, capsule polysaccharide; ESBL, extended-spectrum β-lactamase; MLST, multilocus sequence type; OmpK35(IS), OmpK35 interrupted by insertion sequence; OmpK36GD, OmpK36 Gly134-Asp135 (GD) insertion variant; ST, sequence type; WT, wild-type.

Main Article

Page created: February 18, 2025
Page updated: March 24, 2025
Page reviewed: March 24, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external